Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study-Reference-Cited by-同舟云学术

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Published:2021-07 Issue:7 Volume:22 Page:919-930
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Balar Arjun V,Kamat Ashish M,Kulkarni Girish S,Uchio Edward M,Boormans Joost L,Roumiguié Mathieu,Krieger Laurence E M,Singer Eric A,Bajorin Dean F,Grivas Petros,Seo Ho Kyung,Nishiyama Hiroyuki,Konety Badrinath R,Li Haojie,Nam Kijoeng,Kapadia Ekta,Frenkl Tara,de Wit Ronald

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Epidemiology of bladder cancer;Saginala;Med Sci (Basel),2020

2. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline;Chang;J Urol,2016

3. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016;Babjuk;Eur Urol,2017

4. Management of carcinoma in situ of the bladder: best practice and recent developments;Tang;Ther Adv Urol,2015

5. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study;Lamm;J Urol,2000

Cited by 316 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma;New England Journal of Medicine;2024-09-14

2. Narrative review of value frameworks in urothelial carcinoma and positioning of enfortumab vedotin;Journal of Medical Economics;2024-09-11

3. Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer;Cancers;2024-09-04

4. Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926;Journal of Clinical Oncology;2024-09-03

5. An Overview of Immune Checkpoint Inhibitor Toxicities in Bladder Cancer;Toxicology Reports;2024-09